top of page
Medical Checkup

ASPIRE

Trial Enrolment Status

OPEN

Disease Under Study

Chronic Cough

Duration

​

About the Trial

This is a phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy, safety, and tolerability of Taplucainium Inhalation Powder (NOC-110) once daily in adults with refractory or unexplained chronic cough.

Mechanism of Action:

​

Duration of Study

​

Phase

2b

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Kristen Palandra

Dr. Philteos and Associates | Dynamic Drug Advancement Limited

Address:

Hours:

601 Harwood Avenue South, Suite 201

Ajax, Ontario L1S 2J5

M-F:

9:00am - 5:00pm

Closed on statutory holidays

Main Office Phone: 

 

 

Main Office Fax:   

Clinical Trial Phone:

Clinical Trial Fax: 

Dr. Philteos: (905) 427-1419

Dr. Chelvanathan: (905) 239 0225

Dr. O'Loghlen: (905) 239 0221

(905) 427-0346

(365) 885-9086

(905) 239-2399

©2022 by Dynamic Drug Advancement. Proudly created with Wix.com

bottom of page